scholarly journals Cell transplantation: regulatory aspects, prospects and trends in the clinical use

2013 ◽  
Vol 1 (1) ◽  
pp. 44-46 ◽  
Author(s):  
Yu. Polyachenko ◽  
O. Nikonenko ◽  
R. Salyutin ◽  
M. Komarov ◽  
S. Palyanitsya ◽  
...  
Keyword(s):  
Cell Transplantation ◽  
Clinical Application ◽  
Regulatory Framework ◽  
Clinical Use ◽  
Regulatory Aspects ◽  
Current State ◽  
Cell Technologies

This is review of the current state of cell and tissue technologies in Ukraine and in other countries. The advances and problems of domestic and foreign regulatory framework of this field are discussed in a framework of the legislations governing research and clinical application of cell technologies in Ukraine.

scholarly journals Making Meaningful Clinical Use of Biomarkers

2017 ◽  
Vol 12 ◽  
pp. 117727191771523 ◽  
Author(s):  
Matthew J Selleck ◽  
Maheswari Senthil ◽  
Nathan R Wall
Keyword(s):  
Biomarker Discovery ◽  
Therapeutic Monitoring ◽  
Clinical Use ◽  
Current State

This review discusses the current state of biomarker discovery for the purposes of diagnostics and therapeutic monitoring. We underscore relevant challenges that have defined the gap between biomarker discovery and meaningful clinical use. We highlight recent advancements in and propose a way to think about future biomarker development.

scholarly journals Biomarkers in Posttraumatic Stress Disorder: Overview and Implications for Future Research

2013 ◽  
Vol 35 ◽  
pp. 43-54 ◽  
Author(s):  
Ulrike Schmidt ◽  
Sebastian F. Kaltwasser ◽  
Carsten T. Wotjak
Keyword(s):  
Posttraumatic Stress Disorder ◽  
Sexual Abuse ◽  
Anxiety Disorder ◽  
Posttraumatic Stress ◽  
Stress Disorder ◽  
Future Research ◽  
Clinical Use ◽  
Current State ◽  
Life Threatening ◽  
State Of Research

PTSD can develop in the aftermath of traumatic incidents like combat, sexual abuse, or life threatening accidents. Unfortunately, there are still no biomarkers for this debilitating anxiety disorder in clinical use. Anyhow, there are numerous studies describing potential PTSD biomarkers, some of which might progress to the point of practical use in the future. Here, we outline and comment on some of the most prominent findings on potential imaging, psychological, endocrine, and molecular PTSD biomarkers and classify them into risk, disease, and therapy markers. Since for most of these potential PTSD markers a causal role in PTSD has been demonstrated or at least postulated, this review also gives an overview on the current state of research on PTSD pathobiology.

Cell technologies in the treatment of hip osteoarthritis

MedAlliance ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 29-33
Keyword(s):  
Clinical Trials ◽  
Clinical Practice ◽  
Hip Osteoarthritis ◽  
Current State ◽  
International Registry ◽  
Cell Technologies ◽  
The Subject ◽  
Common Clinical Practice ◽  
Clinical Experiment

SummaryThe article is dedicated to the current state and prospects of cell technologies in the treatment of hip osteoarthritis. The material is based on the analysis of clinical trials on this topic submitted to international registry СlinicalTrials.gov. It has been founded 5 clinical trials relevant to the theme. Only one of these trials was completed with the results pub-lished. It has been stated that the use of cell technologies for the treatment of hip osteoarthritis is still in the stage of a pilot clinical experiment. Thus, it can not yet be the subject of any translation into common clinical practice. At the same time, there is a reason to expect in the upcoming years a serious progress in this direction. This is indicated by the fact that, as of March 1, 2020, the СlinicalTrials.govregistry lists 4 active clinical trials in which the usage of cell technologies in the treatment of hip osteoarthritis is tested. Some of these trials have been already recruiting patients or are ready to begin the recruitment.

The Applicability of Experimental Experience with the Total Artificial Heart to its Clinical Use

1992 ◽  
Vol 15 (5) ◽  
pp. 307-311 ◽  
Author(s):  
J. Vašků ◽  
P. Urbánek ◽  
M. Dostál ◽  
Jan Vašků
Keyword(s):  
Clinical Application ◽  
Artificial Heart ◽  
Venous Pressure ◽  
Early Period ◽  
Total Artificial Heart ◽  
Blood Coagulation Disorders ◽  
Clinical Use ◽  
Long Term Experiments ◽  
Long Term Experiment

Long-term experiments with the total artificial heart (TAH) are a source of valuable knowledge for later clinical application. Our observations result from 66 long-term experiments on calves and one goat ranging from 30 to 314 days, which have shown the main possible complications in the early period (one month) and later in the experiment. Problems until the second month of pumping concern the clinical pendant of the TAH as a bridge for transplantation, i.e. surgical problems, blood coagulation disorders, infection etc. Later problems are high venous pressure or arterial hypertension, infection with septic thromboembolization, mineralization of the driving diaphragm, etc., and are more closely comparable to the conditions of permanent clinical use of the TAH. Faultless surgery, device function and the regimen of pumping are essential factors in every long-term experiment, just as in clinical application. Infection is a threat throughout any experiment, as in clinical cases. The TNS-BRNO-VII/clin/80 TAH has been implanted in six patients.

scholarly journals Carbapenems: Past, Present, and Future

2011 ◽  
Vol 55 (11) ◽  
pp. 4943-4960 ◽  
Author(s):  
Krisztina M. Papp-Wallace ◽  
Andrea Endimiani ◽  
Magdalena A. Taracila ◽  
Robert A. Bonomo
Keyword(s):  
Antimicrobial Activity ◽  
State Of The Art ◽  
Parent Compound ◽  
Antimicrobial Properties ◽  
Value Added ◽  
Clinical Use ◽  
Continue Development ◽  
Penicillin Binding Proteins ◽  
Current State ◽  
Initial Discovery

ABSTRACTIn this review, we summarize the current “state of the art” of carbapenem antibiotics and their role in our antimicrobial armamentarium. Among the β-lactams currently available, carbapenems are unique because they are relatively resistant to hydrolysis by most β-lactamases, in some cases act as “slow substrates” or inhibitors of β-lactamases, and still target penicillin binding proteins. This “value-added feature” of inhibiting β-lactamases serves as a major rationale for expansion of this class of β-lactams. We describe the initial discovery and development of the carbapenem family of β-lactams. Of the early carbapenems evaluated, thienamycin demonstrated the greatest antimicrobial activity and became the parent compound for all subsequent carbapenems. To date, more than 80 compounds with mostly improved antimicrobial properties, compared to those of thienamycin, are described in the literature. We also highlight important features of the carbapenems that are presently in clinical use: imipenem-cilastatin, meropenem, ertapenem, doripenem, panipenem-betamipron, and biapenem. In closing, we emphasize some major challenges and urge the medicinal chemist to continue development of these versatile and potent compounds, as they have served us well for more than 3 decades.

scholarly journals Engineered Extracellular Vesicles: Tailored-Made Nanomaterials for Medical Applications

Nanomaterials ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. 1838
Author(s):  
Kenny Man ◽  
Mathieu Y. Brunet ◽  
Marie-Christine Jones ◽  
Sophie C. Cox
Keyword(s):  
Extracellular Vesicles ◽  
Tissue Regeneration ◽  
State Of The Art ◽  
Medical Applications ◽  
Clinical Use ◽  
Current State ◽  
Pathological Conditions ◽  
Potential Efficacy ◽  
Biomimetic Nanoparticles ◽  
Natural Cell

Extracellular vesicles (EVs) are emerging as promising nanoscale therapeutics due to their intrinsic role as mediators of intercellular communication, regulating tissue development and homeostasis. The low immunogenicity and natural cell-targeting capabilities of EVs has led to extensive research investigating their potential as novel acellular tools for tissue regeneration or for the diagnosis of pathological conditions. However, the clinical use of EVs has been hindered by issues with yield and heterogeneity. From the modification of parental cells and naturally-derived vesicles to the development of artificial biomimetic nanoparticles or the functionalisation of biomaterials, a multitude of techniques have been employed to augment EVs therapeutic efficacy. This review will explore various engineering strategies that could promote EVs scalability and therapeutic effectiveness beyond their native utility. Herein, we highlight the current state-of-the-art EV-engineering techniques with discussion of opportunities and obstacles for each. This is synthesised into a guide for selecting a suitable strategy to maximise the potential efficacy of EVs as nanoscale therapeutics.

Comment on Risk versus Hazard – How to Regulate in the 21st Century

2011 ◽  
Vol 2 (2) ◽  
pp. 193-195
Author(s):  
Dennis Paustenbach ◽  
Julie Panko
Keyword(s):  
21St Century ◽  
Regulatory Process ◽  
Regulatory Framework ◽  
Individual Member ◽  
Technical Knowledge ◽  
Market Place ◽  
Current State ◽  
European Regulatory ◽  
The Individual ◽  
The Eu

In this issue of the journal, Dr. Ragnar Lofstedt examines the current state of the EU regulatory framework with respect to chemicals and illustrates how the hazard-based approach sealed the fate of two important chemicals in the EU market-place. He also explores how the attitudes, technical knowledge and economic influences of the individual member states determine the outcome of environmental and chemical regulations. Lastly, Dr. Lofstedt provides some recommendations to improve consistency in the European regulatory process and ensure greater scientific, as well as, risk-based regulations.

Mesothelial Cells from Tunica Vaginalis, a Practical Source for Mesothelial Transplantation

2007 ◽  
Vol 30 (6) ◽  
pp. 495-500 ◽  
Author(s):  
T. Asano ◽  
R. Takazawa ◽  
M. Yamato ◽  
K. Kihara ◽  
T. Okano
Keyword(s):  
Cell Transplantation ◽  
Fetal Development ◽  
Mesothelial Cell ◽  
Mesothelial Cells ◽  
Clinical Use ◽  
Tunica Vaginalis ◽  
Physiological Conditions ◽  
Reliable Source ◽  
Novel Method ◽  
Near Future

Transplantation of mesothelial cells is used to repair peritoneum that is damaged by surgery, peritonitis, and peritoneal dialysis. The largest obstacle for clinical application of mesothelial cell transplantation is the lack of a reliable source of mesothelial cells. So far, they are isolated from omentum, mesentery, parietal wall and ascites. Procedures used to obtain mesothelial cells from the omentum or mesentery are invasive, however, especially in pre-operative situations. Sufficient amounts of ascites for aspiration can not be obtained under physiological conditions. We have developed a novel method of isolating mesothelial cells from the tunica vaginalis. The tunica vaginalis originates from the peritoneum and descends into the scrotum along with the testis during fetal development. This region provides a source of mesothelial cells that is convenient to approach and free from abdominal complications. Transplantation of autologous mesothelial cells that were isolated from tunica vaginalis was effective in preventing post-operative adhesions. In this review, we summarize mesothelial cell transplantation trials and describe the method of isolating mesothelial cells form the tunica vaginalis. Mesothelial cell transplantation might be widely accepted for clinical use in the near future.

Clinical use of cardiac PET/MRI: current state-of-the-art and potential future applications

2018 ◽  
Vol 36 (5) ◽  
pp. 313-323 ◽  
Author(s):  
Patrick Krumm ◽  
Stefanie Mangold ◽  
Sergios Gatidis ◽  
Konstantin Nikolaou ◽  
Felix Nensa ◽  
...  
Keyword(s):  
State Of The Art ◽  
Clinical Use ◽  
Cardiac Pet ◽  
Current State
Sign in / Sign up

Export Citation Format

Share Document